当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2019年第33期
编号:13439167
晚期原发性肝癌药物研究进展(5)
http://www.100md.com 2019年11月25日 《中国医药导报》 2019年第33期
     [16] Duffy AG,Ulahannan SV,Makorova-Rusher O,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma [J]. J Hepatol,2017,66(3):545-551.

    [17] Ager A,Watson HA,Wehenkel SC,et al. Homing tosolid cancers:a vascular checkpoint in adoptive cell therapy using CAR T-cells [J]. Biochem Soc Trans,2016,44(2):377-385.

    [18] Liu H,Xu Y,Xiang J,et al. Targeting Alpha Fetoprotein (AFP)-MHC complex with CART-Cell therapy for liver cancer [J]. Clin Cancer Res,2017,23(2):478-488.

    [19] Pan K,Li YQ,Wang W,et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients [J]. Ann Surg Oncol,2013,20(13):4305-4311.

    [20] Lee JH,Lee JH,Lim YS,et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma [J]. Gastroenterology,2015,148(7):1383-1391.

    [21] Zerbini A,Pilli M,Laccabue D,et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response [J]. Gastroenterology,2010, 138(5):1931-1942.

    (收稿日期:2019-06-25 本文編辑:刘明玉), 百拇医药(张稳稳 郑曦孜 郑小红)
上一页1 2 3 4 5